Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-315P is a processed pseudogene derived from the U6 small nuclear RNA (snRNA) gene family. Unlike functional U6 snRNA, which is a critical component of the spliceosome and involved in pre-mRNA splicing, RNU6-315P does not code for a functional RNA and does not participate in cellular processes such as splicing. U6 snRNA pseudogenes are believed to arise through retrotransposition events and are common in vertebrate genomes, serving as evolutionary markers rather than active molecular agents. There is no evidence that RNU6-315P is used as a therapeutic target or biomarker, nor is it associated with drug interactions, safety concerns, or relevant disease biology. The presence of the "pseudogene" designation means it carries sequence similarity to the functional gene but lacks functional activity and is not an actionable molecular target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 315, pseudogene (RNU6-315P).